Charles Schwab’s IN8bio INAB Stock Holding History

Charles Schwab’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-437	Closed	-$11.1K	–	3539
2024 Q2	$11.1K	Hold	437	–	–	﹤0.01%	3609
2024 Q1	$15.5K	Hold	437	–	–	﹤0.01%	3444
2023 Q4	$18.1K	Hold	437	–	–	﹤0.01%	3491
2023 Q3	$13.6K	Hold	437	–	–	﹤0.01%	3542
2023 Q2	$20.2K	Buy	+437	New	+$27.3K	﹤0.01%	3558

Other funds holding INAB

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIG

Stonegate Investment Group Birmingham, Alabama $4.31B AUM 18.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Charles Schwab's INAB Position: Q3 2024 in Review

Charles Schwab sold out of IN8bio (INAB) in Q3 2024, closing a stake of 437 shares — an estimated $11.1K sold.

Charles Schwab first reported a position in INAB in Q2 2023 and held it in 5 quarters. The position peaked at $20.2K in Q2 2023. 26 funds tracked by Wall St. Rank hold INAB as of Q3 2024.

Charles Schwab reported no remaining IN8bio position as of Q3 2024 after selling out during the quarter.
Charles Schwab sold 437 IN8bio shares in Q3 2024, an estimated $11.1K.
Charles Schwab first reported a position in IN8bio in Q2 2023 and held it in 5 quarters.
Charles Schwab's IN8bio position peaked at $20.2K in Q2 2023.
26 funds tracked by Wall St. Rank held IN8bio as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.